Detalhe da pesquisa
1.
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer.
Cell
; 174(2): 422-432.e13, 2018 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909987
2.
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.
Hum Mol Genet
; 32(3): 489-495, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018819
3.
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
Cancer
; 130(9): 1629-1641, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38161319
4.
Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms.
Am J Hum Genet
; 108(11): 2071-2085, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699744
5.
TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.
Oncologist
; 29(1): 8-14, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37462445
6.
The effect of limited english proficiency on prostate-specific antigen screening in American men.
World J Urol
; 42(1): 54, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244128
7.
Allele-Specific QTL Fine Mapping with PLASMA.
Am J Hum Genet
; 106(2): 170-187, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32004450
8.
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
Qual Life Res
; 32(11): 3209-3221, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410340
9.
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Prostate
; 81(10): 683-693, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33956343
10.
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
J Urol
; 206(1): 80-87, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683939
11.
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Br J Cancer
; 122(4): 555-563, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857723
12.
Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Prostate
; 79(1): 73-80, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30141208
13.
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
Cancer
; 125(4): 524-532, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427533
14.
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial.
J Med Internet Res
; 21(5): e12044, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31045501
15.
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
Prostate
; 2018 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29882250
16.
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
JAMA
; 319(9): 896-905, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29509865
17.
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions.
Hum Mol Genet
; 24(19): 5603-18, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26162851
18.
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Prostate
; 77(13): 1303-1311, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28762529
19.
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
Cancer
; 123(18): 3532-3539, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28608931
20.
A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer.
Prostate
; 76(14): 1338-41, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325180